<DOC>
	<DOC>NCT01723579</DOC>
	<brief_summary>This study will investigate the efficacy and safety of the monophasic combined oral contraceptive (COC) containing 2.5 mg NOMAC and 1.5 mg E2 in healthy fertile Indian women.</brief_summary>
	<brief_title>Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)</brief_title>
	<detailed_description />
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Sexually active and at risk for pregnancy Of Indian descent, born in India, never emigrated out of India, with Indian home address Body mass index (BMI) ≥17 and ≤35 kg/m^2 Presence or history of venous or arterial thrombotic/thromboembolic events or cerebrovascular accident Presence or history of prodromi of a thrombosis History of migraine with focal neurological symptoms Diabetes mellitus with vascular involvement Presence of a severe or multiple risk factor(s) for venous or arterial thrombosis Severe hypertension Severe dyslipoproteinemia Presence or history of pancreatitis associated with severe hypertriglyceridemia Presence or history of severe hepatic disease Undiagnosed vaginal bleeding Known or suspected pregnancy Currently breastfeeding or breastfeeding within 2 months of starting trial medication Investigational drug use or participation in another clinical trial within 2 months of signing Informed Consent Form for current trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>